Last reviewed · How we verify
MCI-9042
MCI-9042 is a selective inhibitor of transthyretin (TTR) amyloid fibril formation that prevents the aggregation and deposition of misfolded transthyretin protein.
MCI-9042 is a selective inhibitor of transthyretin (TTR) amyloid fibril formation that prevents the aggregation and deposition of misfolded transthyretin protein. Used for Transthyretin amyloidosis (ATTR amyloidosis).
At a glance
| Generic name | MCI-9042 |
|---|---|
| Also known as | Sarpogrelate(INN), ANPLAG(R) |
| Sponsor | Tanabe Pharma Corporation |
| Drug class | Transthyretin stabilizer |
| Target | Transthyretin (TTR) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
MCI-9042 binds to transthyretin and stabilizes its native tetrameric structure, preventing dissociation into monomers that would otherwise misfold and aggregate into amyloid fibrils. By inhibiting TTR amyloid fibril formation, the drug aims to slow or halt the progression of transthyretin amyloidosis, a progressive neurodegenerative disease caused by accumulation of amyloid deposits in peripheral nerves and other tissues.
Approved indications
- Transthyretin amyloidosis (ATTR amyloidosis)
Common side effects
- Peripheral neuropathy progression
- Gastrointestinal disorders
- Fatigue
Key clinical trials
- A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery Disease (PHASE4)
- Multicenter, Therapeutic Use Observational Study to Evaluate the Effects of Concurrent Therapy of Sarpogrelate
- Comparison of the Improvement and Safety of the Ankle Brachial Arterial Pressure Index of Sarpogrelate and Clopidogrel in Stroke Patients With Decreased Ankle Brachial Arterial Pressure Index and Intermittent Claudication of Lower Limb Vascular Atherosclerosis. (NA)
- Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease (PHASE4)
- Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study) (PHASE4)
- A Study to Evaluate the Effect of Sarpogrelate on Blood Hyperviscosity (PHASE4)
- Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fed Conditions (PHASE1)
- Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |